A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms. Academic Article uri icon

abstract

  • We propose a Bayesian population modeling and virtual bioequivalence assessment approach to establishing dissolution specifications for oral dosage forms. A generalizable semi-physiologically based pharmacokinetic absorption model with six gut segments and liver, connected to a two-compartment model of systemic disposition for bupropion hydrochloride oral dosage forms was developed. Prior information on model parameters for gut physiology, bupropion physicochemical properties, and drug product properties were obtained from the literature. The release of bupropion hydrochloride from immediate-, sustained- and extended-release oral dosage forms was described by a Weibull function. In vitro dissolution data were used to assign priors to the in vivo release properties of the three bupropion formulations. We applied global sensitivity analysis to identify the influential parameters for plasma bupropion concentrations and calibrated them. To quantify inter- and intra-individual variability, plasma concentration profiles in healthy volunteers that received the three dosage forms, each at two doses, were used. The calibrated model was in good agreement with both in vitro dissolution and in vivo exposure data. Markov Chain Monte Carlo samples from the joint posterior parameter distribution were used to simulate virtual crossover clinical trials for each formulation with distinct drug dissolution profiles. For each trial, an allowable range of dissolution parameters ("safe space") in which bioequivalence can be anticipated was established. These findings can be used to assure consistent product performance throughout the drug product life-cycle and to support manufacturing changes. Our framework provides a comprehensive approach to support decision-making in drug product development.

published proceedings

  • J Pharmacokinet Pharmacodyn

altmetric score

  • 1.35

author list (cited authors)

  • Hsieh, N., Bois, F. Y., Tsakalozou, E., Ni, Z., Yoon, M., Sun, W., ... Chiu, W. A.

citation count

  • 1

complete list of authors

  • Hsieh, Nan-Hung||Bois, Frédéric Y||Tsakalozou, Eleftheria||Ni, Zhanglin||Yoon, Miyoung||Sun, Wanjie||Klein, Martin||Reisfeld, Brad||Chiu, Weihsueh A

publication date

  • December 2021